These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32303994)

  • 21. Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?
    Iannone F; Semeraro A; Carlino G; Santo L; Bucci R; Quarta L; Maruotti N; Zuccaro C; Marsico A; Falappone PCF; Mazzotta D; Cantatore FP; Muratore M; Lapadula G
    Clin Drug Investig; 2019 Jun; 39(6):565-575. PubMed ID: 30941736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Retention Rate of Golimumab in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis in a Real-Life Setting.
    Serrano-Benavente B; Valor L; Del Río Blasco T; Janta I; González Benítez R; Nieto-González JC; Martínez-Barrio J; Ovalles Bonilla JG; Ariza A; López-Longo FJ; Álvaro-Gracia JM; Monteagudo I; González-Fernández CM
    J Clin Rheumatol; 2022 Jan; 28(1):e150-e155. PubMed ID: 33492028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pain Medication and Corticosteroid Use in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis in the United States: A Retrospective Observational Study.
    Hunter T; Nguyen C; Birt J; Smith J; Shan M; Tan H; Lisse J; Isenberg K
    Rheumatol Ther; 2021 Sep; 8(3):1371-1382. PubMed ID: 34312825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement.
    Chimenti MS; Conigliaro P; Caso F; Costa L; Ortolan A; Triggianese P; Tasso M; Fonti GL; Lorenzin MG; Perricone R; Ramonda R
    Clin Rheumatol; 2022 Jan; 41(1):75-84. PubMed ID: 34410550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey.
    Akar S; Kalyoncu U; Dalkilic E; Emmungil H; Aziz A; Esen Y; Koc T
    Immunotherapy; 2021 Jul; 13(10):841-850. PubMed ID: 33955239
    [No Abstract]   [Full Text] [Related]  

  • 26. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
    Haberhauer G; Strehblow C; Fasching P
    Wien Med Wochenschr; 2010 May; 160(9-10):220-4. PubMed ID: 20632149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
    Pombo-Suárez M; Seoane-Mato D; Díaz-González F; Cea-Calvo L; Sánchez-Alonso F; Sánchez-Jareño M; Jovani V; García-Magallón B; Martínez-González O; Campos-Fernández C; Manero J; Díaz-Torne C; Bohórquez C; Ros-Vilamajó I; Pérez-Vera Y; Castrejón I
    Musculoskeletal Care; 2023 Mar; 21(1):189-197. PubMed ID: 35996810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lower concentration of vitamin D is associated with lower DAS28 and VAS-pain scores in patients with inflammatory rheumatic diseases treated with infliximab: a pilot study.
    Miler M; Nikolac Gabaj N; Grazio S; Vahtarić A; Vrtarić A; Grubišić F; Skala Kavanagh H; Doko Vajdić I; Vrkić N
    Rheumatol Int; 2020 Sep; 40(9):1455-1461. PubMed ID: 32462255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Mack M; Goldstein N; Braun J; Kavanaugh A
    Ann Rheum Dis; 2015 Mar; 74(3):538-46. PubMed ID: 24344160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
    Iannone F; Santo L; Anelli MG; Bucci R; Semeraro A; Quarta L; D'Onofrio F; Marsico A; Carlino G; Casilli O; Cacciapaglia F; Zuccaro C; Falappone PC; Cantatore FP; Muratore M; Lapadula G
    Semin Arthritis Rheum; 2017 Aug; 47(1):108-114. PubMed ID: 28216195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Walsh JA; Pei S; Penmetsa GK; Sauer BC; Patil V; Walker JH; Clewell J; Douglas KM; Clegg DO; Cannon GW; Halwani A
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1218-1228. PubMed ID: 31663467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Bhushan V; Lester S; Briggs L; Hijjawi R; Shanahan EM; Pontifex E; Ninan J; Hill C; Cai F; Walker J; Goldblatt F; Wechalekar MD
    Front Med (Lausanne); 2021; 8():708168. PubMed ID: 34646840
    [No Abstract]   [Full Text] [Related]  

  • 33. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
    Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
    Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world effectiveness and safety of golimumab in rheumatoid arthritis treatment: A two-center study in Taiwan.
    Wang CC; Tseng KS; Tsao YP; Chen WS; Lai CC; Sun YS; Liao HT; Chen MH; Tsai CY
    J Chin Med Assoc; 2022 Feb; 85(2):175-182. PubMed ID: 34882100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study.
    Broadwell A; Schechtman J; Conaway D; Kivitz A; Shiff NJ; Black S; Xu S; Langholff W; Schwartzman S; Curtis JR
    BMC Rheumatol; 2023 Mar; 7(1):5. PubMed ID: 36973741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
    Deodhar A; Shiff NJ; Gong C; Chan EKH; Hsia EC; Lo KH; Akawung A; Kim L; Xu S; Reveille JD
    Rheumatol Ther; 2023 Aug; 10(4):983-999. PubMed ID: 37322274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Charles-Schoeman C; Choy E; McInnes IB; Mysler E; Nash P; Yamaoka K; Lippe R; Khan N; Shmagel AK; Palac H; Suboticki J; Curtis JR
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37945286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry.
    Hernandez MV; Sanchez-Piedra C; Garcia-Magallon B; Cuende E; Manero J; Campos-Fernandez C; Martin-Domenech R; Del Pino-Montes J; Manrique S; Castro-Villegas MC; Ruiz-Montesinos D; Sanchez-Alonso F; Diaz-Gonzalez F; Cea-Calvo L; Gómez-Reino JJ;
    Rheumatol Int; 2019 Mar; 39(3):509-515. PubMed ID: 30353269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Furst DE; Kay J; Wasko MC; Keystone E; Kavanaugh A; Deodhar A; Murphy FT; Magnus JH; Hsia EC; Hsu B; Xu S; Rahman MU; Doyle MK
    Rheumatology (Oxford); 2013 Oct; 52(10):1845-55. PubMed ID: 23838027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry.
    Rahman P; Zummer M; Bessette L; Baer P; Haraoui B; Chow A; Kelsall J; Kapur S; Rampakakis E; Psaradellis E; Lehman AJ; Nantel F; Osborne B; Tkaczyk C
    BMJ Open; 2017 Aug; 7(8):e016619. PubMed ID: 28855200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.